Today's Date: June 2, 2023
UNice Celebrates LGBTQ Pride Month   •   INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of SentinelOne, Inc. (S) on Behalf of Investors   •   HESAI DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Hesai   •   ETHNIC CONFLICTS IN NIGERIA: UNMASKING THE PUPPET MASTERS   •   Navidea Biopharmaceuticals, Inc. Receives NYSE American Notice   •   SENTINELONE ALERT: Bragar Eagel & Squire, P.C. is Investigating SentinelOne, Inc. on Behalf of SentinelOne Stockholders and   •   BURGERFI DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Bu   •   CURE HOSTS "AI FOR GOOD" SUPER SESSION TO MAKE SENSE OF BIG DATA AND HIGH TECH AT 2023 BIO INTERNATIONAL CONVENTION ON JUNE 5   •   INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of DZS Inc. (DZSI) on Behalf of Investors   •   56 Trilogy Health Services Communities Earn 2023 AHCA/NCAL Bronze National Quality Award   •   San Francisco Pride Announces Headliners Hayley Kiyoko and Princess Nokia for 53rd Annual SF Pride Parade & Celebration Feat   •   SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Funko, Inc. with Losses of $100,000 to Contact the Firm   •   Kirby McInerney LLP Reminds Investors That a Class Action Lawsuit Has Been Filed on Behalf of LivePerson, Inc. (LPSN) Investors   •   FNKO INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Funko, Inc. Investors with Substantial Losses Have Opp   •   Promoting Diversity and Equity in Cancer Research, Women Leaders in Oncology® and Vaniam Group Announce Recipients of 2023 Y   •   Bijou Ikli named new CEO by Florida Assisted Living Association   •   The Assembly of First Nations and the Government of Canada announce updates to school design standards for schools on-reserve   •   Rapid Dose Announces Proposed Private Placement Financing   •   Hilton brings back exclusive pop-up hotel experience 'Hilton on the Green' to the 2023 RBC Canadian Open   •   Statement from Minister Hutchings on progress in support of rural Canadians
Bookmark and Share

Oxford Nanopore and PathoQuest announce the first steps in a strategic collaboration to bring the first GMP-accredited, nanopore

OXFORD, England , March 21 /Businesswire/ - Oxford Nanopore Technologies plc (Oxford Nanopore) and PathoQuest today announce the agreement of a MOU for a collaboration to commercialise a transformational Integration Site Analysis (ISA) test to better meet the evolving needs of the biopharmaceutical industry and the advancement of biological therapeutics.

This press release features multimedia. View the full release here:

Oxford Nanopore’s technology can, with very high accuracy, read any length of native DNA, enabling the identification and comprehensive sequence assessment of genomic insertion sites without the risk of missing off target integrations that may negatively impact the therapeutic or the patient. Additionally, PathoQuest’s ISA test is positioned to provide significant benefits (speed, accuracy, confidence in the results) compared to traditional sequencing methods.

We are entering the era of personalised medicine and with that, the way in which we develop, manufacture and provide quality control over advanced therapeutics is progressing. Methods that can offer complete characterisation more quickly will ultimately enhance and further improve the drug development pathway. Oxford Nanopore’s rapid, information-rich sequencing is a natural fit for this challenge.

Oxford Nanopore and PathoQuest intend the ISA test to be the first in a line of sequencing-based quality control test solutions targeting the biopharma genetic characterisation and safety markets.

Gordon Sanghera, CEO, Oxford Nanopore Technologies, commented:

“We are excited to be working with PathoQuest to develop and offer the first Good Manufacturing Practice (GMP) accredited Integration Site Analysis test with nanopore sequencing. We believe this will have a significant future impact by improving test accuracy and turnaround times for genetic characterisation for multiple applications in biopharma.”

Jean-François Brepson, CEO, PathoQuest commented:

“As innovator companies continue to bring exciting new therapies to market, there is a critical need for innovative biosafety and characterisation strategies.” Mr. Brepson continued, “This new Integration Site Analysis method, powered by Oxford Nanopore sequencing, will enable our customers to progress their biologics programmes with more certainty than ever before.”

About Oxford Nanopore Technologies

Oxford Nanopore Technologies’ goal is to bring the widest benefits to society through enabling the analysis of anything, by anyone, anywhere. The company has developed a new generation of nanopore-based sensing technology for real-time, high-performance, accessible and scalable analysis of DNA and RNA. The technology is used in more than 120 countries to understand the biology of humans and diseases such as cancer, plants, animals, bacteria, viruses and whole environments. Oxford Nanopore Technologies products are intended for molecular biology applications and are not intended for diagnostic purposes.

Forward-looking statements

This announcement contains certain forward-looking statements. Phrases such as "potential", “expect”, "intend", “believe we can”, “working to”, "anticipate", "when validated", and similar expressions of a future or forward-looking nature should also be considered forward-looking statements. Forward-looking statements address our expected future business, and by definition address matters that are, to different degrees, uncertain and may involve factors beyond our control.

About PathoQuest

With over 20 peer reviewed publications on NGS applications in biosafety testing, PathoQuest is a leading expert in the application of Good Manufacturing Practices (GMP)-compliant next generation sequencing (NGS)-based biosafety testing. PathoQuest offers biopharmaceutical companies a game-changing genomic approach to ensuring the safety of biologics such as cell and gene therapy products, vaccines, and recombinant drugs, ultimately enabling a reduction in the time to market for these innovative treatments. PathoQuest’s technology combines NGS platforms with proprietary sample preparation and data analysis processes to bring novel solutions to the industry. PathoQuest, headquartered in Paris, France, with a US based site in Wayne (PA) has worked with over 100 of the leading biopharmaceutical companies globally.

STORY TAGS: Photo/Multimedia, United Kingdom, Europe, Health, Genetics, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, Contract/Agreement,


White House Live Stream
alsharpton Rev. Al Sharpton
9 to 11 am EST
jjackson Rev. Jesse Jackson
10 to noon CST


Sounds Make the News ®
Atlanta - WAOK-Urban
Berkley / San Francisco - KPFA-Progressive
Chicago - WVON-Urban
KJLH - Urban
Los Angeles - KJLH - Urban
WKDM-Mandarin Chinese
New York - WKDM-Mandarin Chinese
New York - WADO-Spanish
WBAI - Progressive
New York - WBAI - Progressive
Washington - WOL-Urban

Listen to United Natiosns News